Modern stem cell technology is rapidly evolving and holds promise to revolutionize medicine by allowing regeneration of any type of cell within the human body

Vitro Develops Novel Stem Cell Technology for Use in Treatment of Hearing LossPosted on April 14, 2012

Golden, Colorado—October 4, 2011—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced development of technical advancements with application to treatment of hearing loss in animals and human through commercialization of a variety of stem cell products to prevent, reverse and restore hearing in cases of hearing loss.

Hearing reduction or loss is estimated to affect approximately 22 to 36 million individuals globally. Effective treatments of this condition thus represent a multi-billion dollar market that is expected to increase as the population ages. Hearing loss or reduction can occur by several causes including environmental exposure to excessive sound and it is commonly associated with aging. This market is primarily served by providers of digital and analog hearing aids. Digital devices provide improved hearing enhancement to users at increased cost. A predominant cause of hearing loss is presbycusis, a condition thought to result from degeneration of hair cells and other structures in the inner ear that through signaling to the auditory nerve, result in the auditory perceptions underlying hearing. .

Vitro’s therapeutic products include molecular compositions to promote, maintain and restore inner ear hair cells and related structures together with adult stem cell transplantation to restore hearing loss. Vitro’s intellectual property has application to hearing restoration and prevention of hearing loss through a series of products envisioned to provide various treatment options for hearing loss. Vitro’s discoveries may lead to new pharmaceutical agents that stimulate activation of native adult stem cells to regenerate inner ear hair cells, together with other cells derived from adult stem cells, without the necessity of stem cell transplantation. Recombinant cytokines including erythropoietin and granulocyte colony stimulating factor are now widely used for therapeutic activation of the hematopoietic stem cell system for treatment of adverse effects of chemotherapy and represent major products of the biotechnology industry.

Vitro has developed other proprietary technology related to stem cell products and technology with broad application to various areas in medical research and therapy. Modern stem cell technology is rapidly evolving and holds promise to revolutionize medicine by allowing replacement of any type of cell within the human body. Diseases characterized by cellular degeneration, including Alzheimer’s disease, cardiovascular disease, heart attack, stroke, diabetes, spinal cord injury, acute and chronic kidney failure, hearing loss, macular degeneration and several other disorders may be treatable through the development and further commercialization of stem cell technology.

While the research and use of human embryonic stem cells is highly contentious and ethically controversial, Vitro’s stem cell technology is based on adult human stem cells that are derived without sacrifice of embryos needed to generate embryonic stem cells. Transplantation of adult stem cells, derived from various tissues including bone marrow, has been used for the past fifty years to treat leukemia, lymphoma and other blood disorders and is now a widely available treatment option for several forms of blood cancer and autoimmune diseases. New developments in stem cell technology, including Vitro’s patent-pending technology, are leading the way to novel technologies using adult stem cells to provide the benefits of embryonic stem cells including the ability to differentiate into any cell of the body. This occurs through reprogramming of adult cells to become functionally equivalent to embryonic stem cells. Such technology eliminates the basis of the current ethical, religious and political issues associated with the use of embryonic stem cells while capturing their clinical advantages. The Company is seeking appropriate partnerships to commercialize its stem cell products related to treatment of hearing loss.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(303) 999-2130 Ext. 3
E-mail: jim@vitrodiag.com

Source: Vitro Diagnostics, Inc.

Tags: ,